Emergent Biosolutions, Inc. (EBS) Financials

EBS Assets vs Liabilities

DateAssetsLiabilities
2024-03-31 1.8 billion 1.1 billion
2023-12-31 1.8 billion 1.2 billion
2023-09-30 1.9 billion 1.2 billion
2023-06-30 2.2 billion 1.2 billion

EBS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2024-03-31 -73.4 million 5.9 million
2023-12-31 20.7 million 4.0 million
2023-09-30 47.4 million 4.0 million
2023-06-30 -126.9 million 8.3 million

EBS Net Income

Graph available only for supporters. Become a supporter to see it.
DateNet Income
2024-03-31 9.0 million
2023-12-31 -49.5 million
2023-09-30 -263.4 million
2023-06-30 -261.3 million

EBS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2024-03-31 78.5 million - -
2023-12-31 111.7 million - -
2023-09-30 87.8 million - -
2023-06-30 88.6 million 448.0 million -

EBS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2024-03-31 52.2 million
2023-12-31 51.9 million
2023-09-30 51.8 million
2023-06-30 50.7 million

EBS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2024-03-31 10.8 million 15.1 million - -
2023-12-31 11.4 million 29.2 million 89.7 million -
2023-09-30 12.6 million 15.3 million 86.0 million -
2023-06-30 12.5 million 26.0 million 91.4 million -

EBS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2024-03-31 300.4 million 159.5 million
2023-12-31 276.6 million 201.8 million
2023-09-30 270.5 million 176.8 million
2023-06-30 337.9 million 190.6 million

EBS

Price: $3.89

52 week price:
1.42
12.94

Earnings Per Share: -14.85 USD

P/E Ratio: -0.10

Exchange: NYQ

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 633400

Ebitda: 58.1 million

Market Capitalization: 172.9 million

Links: